Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 20 12 2020
accepted: 27 07 2021
entrez: 13 10 2021
pubmed: 14 10 2021
medline: 25 11 2021
Statut: epublish

Résumé

Staphylococcus aureus is a major cause of serious illness and death in children, indicating the need to monitor prevalent strains, particularly in the vulnerable pediatric population. Nasal carriage of S. aureus is important as carriers have an increased risk of serious illness due to systemic invasion by this pathogen and can transmit the infection. Recent studies have demonstrated the effectiveness of azithromycin in reducing the prevalence of nasopharyngeal carrying of pneumococci, which are often implicated in respiratory infections in children. However, very few studies of the impact of azithromycin on staphylococci have been undertaken. During a clinical trial under taken in 2016, nasal swabs were collected from 778 children aged 3 to 59 months including 385 children who were swabbed before administration of azithromycin or placebo and 393 after administration of azithromycin or placebo. Azithromycin was given in a dose of 100 mg for three days, together with the antimalarials sulfadoxine-pyrimethamine and amodiaquine, on four occasions at monthly intervals during the malaria transmission season. These samples were cultured for S. aureus as well as for the pneumococcus. The S. aureus isolates were tested for their susceptibility to azithromycin (15 g), penicillin (10 IU), and cefoxitine (30 g) (Oxoid Ltd). S. aureus was isolated from 13.77% (53/385) swabs before administration of azithromycin and from 20.10% (79/393) six months after administration (PR = 1.46 [1.06; 2.01], p = 0.020). Azithromycin resistance found in isolates of S. aureus did not differ significantly before and after intervention (26.42% [14/53] vs 16.46% [13/79], (PR = 0.62 [0.32; 1.23], p = 0.172). Penicillin resistance was very pronounced, 88.68% and 96.20% in pre-intervention and in post-intervention isolates respectively, but very little Methicillin Resistance (MRSA) was detected (2 cases before and 2 cases after intervention). Monitoring antibiotic resistance in S. aureus and other bacteria is especially important in Burkina Faso due to unregulated consumption of antibiotics putting children and others at risk.

Identifiants

pubmed: 34644317
doi: 10.1371/journal.pone.0257190
pii: PONE-D-20-33805
pmc: PMC8513893
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antimalarials 0
Azithromycin 83905-01-5

Banques de données

ClinicalTrials.gov
['NCT02211729']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0257190

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

N Engl J Med. 2019 Jun 06;380(23):2271-2273
pubmed: 31167060
PLoS One. 2017 Jan 20;12(1):e0170320
pubmed: 28107412
Med Sante Trop. 2012 Oct-Dec;22(4):425-9
pubmed: 23360620
N Engl J Med. 2020 Nov 12;383(20):1941-1950
pubmed: 33176084
Clin Infect Dis. 2013 Jun;56(11):1519-26
pubmed: 23487375
Antimicrob Agents Chemother. 2003 Sep;47(9):2765-9
pubmed: 12936971
Br J Ophthalmol. 2003 Feb;87(2):147-8
pubmed: 12543738
Lancet Infect Dis. 2016 Jun;16(6):703-711
pubmed: 26897105
Pediatr Infect Dis J. 1999 Oct;18(10 Suppl):S35-41
pubmed: 10530572
N Engl J Med. 2019 Jun 06;380(23):2197-2206
pubmed: 30699301
BMC Res Notes. 2017 Dec 19;10(1):746
pubmed: 29258622
BMC Infect Dis. 2019 Dec 2;19(1):1023
pubmed: 31791276
Bull World Health Organ. 2014 Jul 1;92(7):490-8
pubmed: 25110374
Clin Infect Dis. 1997 Mar;24(3):356-62
pubmed: 9114185
J Pediatr. 2013 Jul;163(1 Suppl):S4-7
pubmed: 23773593
Emerg Infect Dis. 2019 Apr;25(4):701-709
pubmed: 30882307
Trop Med Int Health. 2019 Dec;24(12):1442-1454
pubmed: 31655020
JAMA. 2009 Sep 2;302(9):962-8
pubmed: 19724043
Clin Infect Dis. 2011 Apr 1;52(7):883-8
pubmed: 21427395

Auteurs

Soumeya Hema-Ouangraoua (S)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso.

Juliette Tranchot-Diallo (J)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso.
Université Nazi Boni, Bobo-Dioulasso, Burkina Faso.

Issaka Zongo (I)

Institut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.

Nongodo Firmin Kabore (NF)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso.

Frédéric Nikièma (F)

Institut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.

Rakiswende Serge Yerbanga (RS)

Institut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.

Halidou Tinto (H)

Institut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.

Daniel Chandramohan (D)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Georges-Anicet Ouedraogo (GA)

Université Nazi Boni, Bobo-Dioulasso, Burkina Faso.

Brian Greenwood (B)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Jean-Bosco Ouedraogo (JB)

Institut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH